© 2020 Ksenija NesicHigh-Grade Serous Ovarian Carcinoma (HGSOC) is the most common subtype of ovarian cancer, and is the leading cause of ovarian cancer death. This subtype is molecularly characterised by frequent loss of Homologous Recombination (HR) DNA repair, making it susceptible to Poly-ADP ribose polymerase (PARP) inhibitor treatment. Despite the efficacy of PARP inhibitors (PARPi) in treating HGSOC, disease recurrence is common. A poor understanding of PARPi toxicity and resistance mechanisms has limited improvements in overall survival of patients. This project utilised HGSOC Patient-Derived Xenograft (PDX) and in vitro models to determine underlying mechanisms of PARPi sensitivity and resistance. Characterisation of the HGSOC PD...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian canc...
Contains fulltext : 202591.pdf (publisher's version ) (Closed access)OBJECTIVE: Po...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian canc...
Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly...
Less than half of patients with epithelial ovarian cancer (EOC) survive five years following diagnos...
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ...
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ...
The advent of molecular targeted therapies has made a significant impact on survival of women with o...
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ...
The presence of a BRCA mutation, somatic or germline, is now established as a standard of care for s...
Ovarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic feature...
Defective DNA repair via homologous recombination (HR) is common in ovarian high grade serous carcin...
The presence of a BRCA mutation, somatic or germline, is now established as a standard of care for s...
Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results fr...
Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian canc...
Contains fulltext : 202591.pdf (publisher's version ) (Closed access)OBJECTIVE: Po...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian canc...
Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly...
Less than half of patients with epithelial ovarian cancer (EOC) survive five years following diagnos...
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ...
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ...
The advent of molecular targeted therapies has made a significant impact on survival of women with o...
Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ...
The presence of a BRCA mutation, somatic or germline, is now established as a standard of care for s...
Ovarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic feature...
Defective DNA repair via homologous recombination (HR) is common in ovarian high grade serous carcin...
The presence of a BRCA mutation, somatic or germline, is now established as a standard of care for s...
Acquired PARP inhibitor (PARPi) resistance in BRCA1- or BRCA2-mutant ovarian cancer often results fr...
Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian canc...
Contains fulltext : 202591.pdf (publisher's version ) (Closed access)OBJECTIVE: Po...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian canc...